Santos da Silva Jorge

Chief Executive Officer

Santos da Silva Jorge has filed 5 SEC Form 4 filings (9 transaction rows) across 1 company, with disclosures dating back to 2025. 5 of those filings fall inside the rolling window. Most recent filing: Jul 13, 2026.

On the most recent filing, Santos da Silva Jorge is listed as Chief Executive Officer at MoonLake Immunotherapeutics. Inside the rolling window, Santos da Silva Jorge reported no open-market purchases and 7 open-market sales totaling $8.7M in MLTX. The largest disclosed transaction in the window is a sale of 130,000 MLTX shares on Dec 8, 2025, worth $2.0M.

Companies traded

Other insiders at MLTX

Insider Buying

$0

reported purchases (SEC code P)

Insider Selling

$8.7M

reported sales (SEC code S)

Companies

1

in the rolling window

Source
MLTXSale$679KJul 13SEC ↗
MLTXSale$1.4MJul 13SEC ↗
MLTXSale$957KJul 2SEC ↗
MLTXSale$1.8MApr 14SEC ↗
MLTXSale$946KApr 14SEC ↗
MLTXSale$2.0MDec 10SEC ↗
MLTXSale$1.0MDec 10SEC ↗

Frequently asked questions

How many SEC Form 4 filings has Santos da Silva Jorge made?

Santos da Silva Jorge has filed 5 SEC Form 4 filings (9 transaction rows) across 1 company since 2025.

Which companies does Santos da Silva Jorge trade?

Santos da Silva Jorge has filed SEC Form 4 disclosures for 1 company, including MLTX.

When was Santos da Silva Jorge's most recent SEC Form 4 filing?

Santos da Silva Jorge's most recent SEC Form 4 filing on Tracefour is dated Jul 13, 2026.

What is Santos da Silva Jorge's job title?

On the most recent SEC Form 4 filings tracked by Tracefour, Santos da Silva Jorge is listed as Chief Executive Officer.

What is Santos da Silva Jorge's total buy and sell value in the current window?

Inside the rolling retention window, Santos da Silva Jorge bought $0 and sold $8.7M based on SEC Form 4 filings.

What was Santos da Silva Jorge's largest disclosed transaction?

The largest disclosed transaction in the current window is a sale of 130,000 MLTX shares on 2025-12-08, worth $2.0M, per SEC Form 4 filings.